| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/17/2001 | EP1067926A2 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins |
| 01/17/2001 | EP1067922A1 Agents and methods for modulation of zinc transfer by metallothionein |
| 01/17/2001 | EP1067917A2 Method of treating dopaminergic and gaba-nergic disorders |
| 01/17/2001 | EP1067911A1 Hydrogel compositions useful for the sustained release of macromolecules and methods of making same |
| 01/17/2001 | EP1067894A2 Protease inhibitors |
| 01/17/2001 | EP1067893A2 Human galactosyl transferases |
| 01/17/2001 | EP1067879A1 Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
| 01/17/2001 | EP0949910A4 Transmural drug delivery method and apparatus |
| 01/17/2001 | EP0880355A4 Methods of modulating inflammatory cytokines in the cns using tgf-beta |
| 01/17/2001 | EP0771216B1 Methods and compositions for the specific coagulation of tumoral vasculature |
| 01/17/2001 | EP0750514B1 Immunotherapeutic preparations containing gamma globulins for treating cancerous diseases |
| 01/17/2001 | EP0748191A4 Methods and formulations for use in treating oophorectomized women |
| 01/17/2001 | EP0696198B1 Novel polypeptide having factor xa inhibitory activity |
| 01/17/2001 | EP0672158B1 Adenovirus with genetic fusion of penton fibre to peptide altering binding specificity |
| 01/17/2001 | EP0615454B1 Method of preparing a biological adhesive enriched with platelet factors, and application |
| 01/17/2001 | EP0589982B1 Monoclonal antibodies against human tnf-binding protein i (tnf-bp i) |
| 01/17/2001 | CN1280620A Antigen protein and nucleic acid coding for said protein |
| 01/17/2001 | CN1280619A (Chlamydia trachomatic) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| 01/17/2001 | CN1280617A TSA 305 gene |
| 01/17/2001 | CN1280613A Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
| 01/17/2001 | CN1280612A Differentiation of adipose stromal cells into osteobalsts and uses thereof |
| 01/17/2001 | CN1280586A Erythropoietin with high specific activity |
| 01/17/2001 | CN1280511A A one dose syringe, comprising a freeze-dried protein composition, for administering of a volume less than 0.5ml |
| 01/17/2001 | CN1280504A Vaccines with an LTB adjuvant |
| 01/17/2001 | CN1280503A Method of mobilizing hematopoietic stem cells |
| 01/17/2001 | CN1280502A Cyclosporin-containing microemulsion preconcentrate composition |
| 01/17/2001 | CN1280501A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/17/2001 | CN1280500A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/17/2001 | CN1280497A Mammalian-derived peptides for the treatment of microbial infection |
| 01/17/2001 | CN1280493A Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 01/17/2001 | CN1280492A Porous hydroxyapatite particles as carriers for drug substances |
| 01/17/2001 | CN1280490A Peptide/lipid complex formation by co-lyophilization |
| 01/17/2001 | CN1280483A Site-specitic preparation of polyethylene glycol-GRF conjujates |
| 01/17/2001 | CN1280137A Erythrocyte-stimulating factor coupling |
| 01/17/2001 | CN1280136A Gene sequence and amino-acid sequence of varient omega-conch toxin polypeptide and their preparing method and medicinal use |
| 01/17/2001 | CN1280010A Oral medicine for curing diabetes and its producing method |
| 01/17/2001 | CN1280009A Enopeptin containing compound preparation and its medical use for controlling sutaneous pigmentation |
| 01/17/2001 | CN1279954A Arsenic composite preparation suitable for cancer arterial insertion administration and its preparing method |
| 01/17/2001 | CN1060679C Use of combination of angiotensin-converting enzyme inhibitor and calcium antagonist for treatment of proteinuria |
| 01/16/2001 | USRE37020 Administering an elderly patient a protein source, a lipid source includes triglycerides and a carbohydrate source includes a source of dietary fiber, preferably, the protein source includes atleast 18% of the total calories as |
| 01/16/2001 | US6175000 Nucleic acids encoding human trithorax protein |
| 01/16/2001 | US6174996 Fusion protein with reduced side effects; for use as viricides, anticarcinogenic/antitumor/antiproliferative agents in humans and animals; feline leukemia virus; human immunodeficiency virus; hepatitis b and c viruses |
| 01/16/2001 | US6174995 Amino acid sequences of chemokine beta-4 and monocyte chemotactic protein-4; anticarcinogenic/antitumor agents; antifibrotic/antiarthritic/antiinflammatory agents; treatment of chronic infections, autoimmune disorders, psoriasis |
| 01/16/2001 | US6174994 7TM receptor (H2CAA71) |
| 01/16/2001 | US6174993 Short peptides which selectively modulate the activity of serine/threonine kinases |
| 01/16/2001 | US6174916 Methods for treating herpes virus infections |
| 01/16/2001 | US6174915 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| 01/16/2001 | US6174872 Immunotherapy of allergic asthma in both its early and late stages by administering to the mucosa a polynucleotide encoding an asthma-initiating antigen and immunostimulatory neucleotide seqence stimulating the th1 lymhocytes |
| 01/16/2001 | US6174871 Gene therapies for enhancing cardiac function |
| 01/16/2001 | US6174868 Compositions and methods for treatment of hepatitis C virus-associated diseases |
| 01/16/2001 | US6174862 Neuroprotectant administered to patients suffering from alzheimer's disease, human immunodeficiency virus |
| 01/16/2001 | US6174861 Administering anticarcinogenic/antitumor agent |
| 01/16/2001 | US6174859 Method of treatment |
| 01/16/2001 | US6174858 Conjugates useful in the treatment of prostate cancer |
| 01/16/2001 | US6174857 Parenteral mixture comprising insulin-like growth factor i, a bone antiresorptive compound and a carrier |
| 01/16/2001 | US6174856 Stabilized insulin compositions |
| 01/16/2001 | US6174855 Pharmaceutical compositions comprising thrombin inhibitors and their use in the control of wound healing processes |
| 01/16/2001 | US6174721 Protein having kunitz-type domains of tissue factor pathway inhibitors and lacking glycosylation sites; for prevention and treatment of septic shock |
| 01/16/2001 | US6174714 Lyss |
| 01/16/2001 | US6174703 Nucleotide sequences coding a polymerase binding protein; for the treatment of cancer, acquired immune deficiency syndrome, aging and cell proliferative defects |
| 01/16/2001 | US6174701 Neuronal factor |
| 01/16/2001 | US6174691 Deactivating a preferential tumor glycoprotein or a cell expressing preferential glycoprotein; exposing preferential glycoprotein or cell expressing the preferential glycoprotein to a toxic substance |
| 01/16/2001 | US6174689 Viral encoded semaphorin protein receptor DNA and polypeptides |
| 01/16/2001 | US6174687 Methods of identifying lung homing molecules using membrane dipeptidase |
| 01/16/2001 | US6174685 Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use |
| 01/16/2001 | US6174679 CIF150/hTAFII150 is necessary for cell cycle progression |
| 01/16/2001 | US6174676 Cytokine-stress- and oncoprotein-activated human protein kinase kinases |
| 01/16/2001 | US6174539 Localized use of nitric oxide adducts to prevent internal tissue damage |
| 01/16/2001 | US6174529 Oral therapy for the treatment of allergies and method of manufacture |
| 01/16/2001 | US6174527 Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
| 01/16/2001 | CA2313899A1 Novel selective imune down regulation (sidr) mediated transplantation processes, processes for preventing or treating diseases in a subject, and compositions of matter comprising trained or programmed cells, tissues or organs useful for sidr establishment |
| 01/16/2001 | CA2204355C Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 01/16/2001 | CA2200192C Amidino and guanidino substituted inhibitors of trypsin-like enzymes |
| 01/16/2001 | CA2198099C Use of tasteless, hydrolysed collagen and agent containing the same |
| 01/16/2001 | CA2188793C Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof |
| 01/16/2001 | CA2076979C Substantially pure transforming growth factor-.beta.-1-binding protein and nucleotide sequences expressing the binding protein |
| 01/16/2001 | CA2068324C Metal-peptide compositions and methods for stimulating hair growth |
| 01/16/2001 | CA2029861C Diagnosis and treatment of insulin dependent diabetes mellitus |
| 01/16/2001 | CA1341169C Factor viii analog, process for its preparation and composition containing it |
| 01/16/2001 | CA1341166C Antigenic proteins and vaccines containing them for prevention of coccidiosis |
| 01/11/2001 | WO2001002897A1 System, apparatus, and method for correcting vision using electro-active spectacles |
| 01/11/2001 | WO2001002895A1 System, apparatus, and method for correcting vision using an electro-active lens |
| 01/11/2001 | WO2001002866A1 Diagnostics and therapeutics for arterial wall disruptive disorders |
| 01/11/2001 | WO2001002862A1 Methods to detect protein trafficking disorders |
| 01/11/2001 | WO2001002860A1 Snail, new tumoral progression marker and target protein of new antitumoral compounds |
| 01/11/2001 | WO2001002604A1 Use of the krit1 gene in angiogenesis |
| 01/11/2001 | WO2001002601A2 Cell-based assay systems for examining hcv ns3 protease activity |
| 01/11/2001 | WO2001002594A2 DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER |
| 01/11/2001 | WO2001002587A2 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 01/11/2001 | WO2001002578A1 Global regulators of bacterial pathogenic genes; bacterial autoinducer inactivation protein, as targets for engineering disease resistance |
| 01/11/2001 | WO2001002577A1 Pseudomonas aeruginosa antigens |
| 01/11/2001 | WO2001002571A2 An interleukin-1 receptor antagonist and uses thereof |
| 01/11/2001 | WO2001002570A1 Delivery of trefoil peptides |
| 01/11/2001 | WO2001002569A2 Human immune response molecules |
| 01/11/2001 | WO2001002568A2 Human genes and gene expression products |
| 01/11/2001 | WO2001002567A1 16405 receptor, a g-protein coupled receptor |
| 01/11/2001 | WO2001002566A1 Metabotropic glutamate receptors and methods of use therefor |
| 01/11/2001 | WO2001002565A2 Secreted protein zacrp4 |
| 01/11/2001 | WO2001002564A1 Novel polypeptide and dna thereof |
| 01/11/2001 | WO2001002561A2 Mammalian calcium channels and related probes, cell lines and methods |